Lupus Nephritis FocusRheum

SAN FRANCISCO—Rheumatologists have to look no further than the American College of Rheumatology guidelines to know that the options for patients with lupus nephritis are sometimes not very appealing. The first-line choices are either mycophenolate mofetil (MMF) plus glucocorticoids or cyclophosphamide (CYC), also with glucocorticoids—and all of their attendant side effects. The problem: evidence, said…

Due to a lawsuit, the FDA has issued only tentative approval for an extended-release oxycodone capsule. Obinutuzumab is in clinical trials for lupus nephritis, and subcutaneous belimumab is being tested for SLE…

Comparing tacrolimus, mycophenolate mofetil and cyclophosphamide, tacrolimus was the most efficacious. Also, biosimilars may soon be easier to differentiate…

In a recent review, researchers addressed skin injury in patients with SLE, discussing the effects of ultraviolet rays on the skin and the subsequent generation of autoantibodies. They concluded that UV rays activate immune cells where IgG has been deposited, resulting in inflammation…

Important new findings show that a majority of women with inactive or stable SLE can have successful pregnancies without experiencing flares and give birth to infants who survive the neonatal period…

Multi-targeted, aggressive drug therapies needed for complete response, remission of this lupus complication

Rheumatology experts review history of LN, offer explanations for roadblocks to better therapies

Detailed screening and treatment recommendations based on current evidence, extensive literature review.

Panush’s perspectives on selections from the literature

The role of HMGB1 in the pathogenesis of lupus nephritis